NASDAQ: SPPI CLASS ACTION NOTICE: Berger Montague Encourages Spectrum Pharmaceuticals (NASDAQ: SPPI) Investors to Inquire About a Securities Fraud Class Action

Group 1 - The core issue involves securities fraud claims against Spectrum Pharmaceuticals, Inc. related to misleading statements about its Pinnacle Study for the drug poziotinib [1][3] - The class action lawsuit pertains to investors who acquired Spectrum shares between March 17, 2022, and September 22, 2022 [1][2] - Spectrum Pharmaceuticals is primarily focused on oncology treatments [2] Group 2 - Investors have a deadline of September 24, 2025, to seek appointment as lead plaintiff representative in the class action [2] - Following a merger with Assertio Holdings, Inc., Spectrum shares were delisted [3]